Candidiasis Drugs Market Size & Share, by Disease Type (Oral, Vaginal, Cutaneous, Invasive); Drug Type {Butoconazole, Clotrimazole, Miconazole (Monistat, Vagistat), Nystatin, Tioconazole}; End-user (Hospitals, Retail Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3650
  • Published Date: Aug 26, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Candidiasis Drugs Market size was over USD 822.3 million in 2023 and is anticipated to reach USD 1.77 billion by 2036, witnessing around 6.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of candidiasis drugs is estimated at USD 862.43 million. Candida is a yeast, that causes infection in the mucosal layer. The growth of the market can be attributed to the growing cases of yeast infection across the world, backed by poor immunity, sanitation practices, and others. The increasing health awareness, availability of anti-fungal drugs, and growing investment in development of new drugs, is estimated to boost the market growth. Candida is usually present inside the skin, in parts lined with mucous, such as the mouth, throat, gut, and vagina, without causing any problems. Infections are caused when the yeast grows out of control, due to high amount of sugar in blood, high humidity, or poor hygiene. Diabetes is a major factor for candidiasis infection, as raised blood sugar promotes yeast activation. The growing incidences of diabetes is estimated to boost the market growth over the forecast period. According to the report by the World Health Organization (WHO), 422 million people worldwide suffer from diabetes, in countries of all income levels, and around 1.6 million deaths are directly attributed to it each year.


Get more information on this report: Request Free Sample PDF

Candidiasis Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Candidiasis
  • Rising R&D Activities for Drug Development
  • Easy Availability of Anti-fungal Drugs

Challenges

  • Lack of Health Awareness amongst People
  • Absence of Proper Healthcare Infrastructure

Candidiasis Drugs Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

6.1%

Base Year Market Size (2023)

USD 822.3 million

Forecast Year Market Size (2036)

USD 1.77 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
 
Get more information on this report: Request Free Sample PDF

Candidiasis Drugs Segmentation

The market is segmented by disease type into oral, vaginal, cutaneous, invasive, and others, out of which, the vaginal segment is anticipated to hold the notable share in the global candidiasis drugs market over the forecast period on the back of the increasing cases of vaginal candidiasis, backed by lack of sexual health awareness and hygiene amongst individuals, especially in the middle and low-income countries. According to the data by the Center for Disease Control and Prevention (CDC), about 20% women who have candida in the vagina, do not notice any symptoms.

Vaginal candidiasis is not a sexually transmitted disease. It is caused due to poor hygiene, hot and humid environment around the vulva, sharing toilets, and even due to drinking less amount of water. Mild infections are often overlooked, due to the embarrassment and taboo associated with diseases in the private parts, resulting in severe infection and even hospitalization. This is a major factor expected to drive the segment growth. Pregnancy and hormonal contraceptives are also a major cause of candidiasis in the vagina.

Our in-depth analysis of the global candidiasis drug market includes the following segments:

 

          By Disease Type

  • Oral
  • Vaginal
  • Cutaneous
  • Invasive
  • Others

          By Drug Type

  • Butoconazole
  • Clotrimazole
  • Miconazole
    • Monistat
    • Vagistat
    • Others
  • Nystatin
  • Tioconazole
  • Others

           By End-User

 

  • Hospital
  • Retail Pharmacies
  • Others
 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Candidiasis Drugs Industry - Regional Synopsis

On the basis of geographical analysis, the global candidiasis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is predicted to account for largest revenue share by 2036, driven by climatic conditions that promote yeast infection. Moreover, lack of proper sanitation in the region, and lower rate of health awareness, especially in rural parts of the developing countries, is estimated to boost the regional market growth. The market in the Middle East and Africa region is also estimated to witness significant growth owing to the lack of hygiene and sanitation, and hot & humid climate of the region.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the constantly rising cases of candidiasis, especially invasive candidiasis in the region. As per a report by the CDC, approximately 25,000 cases of candidemia are recorded in the United States each year. The high prevalence of diabetes is one of the primary factors for the increasing candidiasis cases in the region.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Candidiasis Drugs Landscape

    • Biogen, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • Glenmark Pharmaceuticals
    • Merck KGaA
    • Novartis AG
    • Sanofi-aventis Groupe
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Company, Limited
    • Siemens Healthcare GmbH

In the News

  • June, 2021: Novartis AG announced its collaboration with Hewlett Packard Enterprise to expand its distribution globally.
  • August, 2017: Sanofi-aventis and Bristol-Myers Squibb Company announced FDA approval for the antiplatelet agent PLAVIX.

Author Credits:  Radhika Pawar


  • Report ID: 3650
  • Published Date: Aug 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of candidiasis drugs is estimated at USD 862.43 million.

Candidiasis Drugs Market size was over USD 822.3 million in 2023 and is anticipated to reach USD 1.77 billion by 2036, witnessing around 6.1% CAGR during the forecast period i.e., between 2024-2036. The increasing cases of candidiasis will boost the market growth.

Asia Pacific industry is predicted to account for largest revenue share by 2036, driven by climatic conditions that promote yeast infection.

The major players in the market are Pfizer Inc., Glenmark Pharmaceuticals, Merck KGaA, Novartis AG, Sanofi-aventis Groupe, Teva Pharmaceutical Industries Ltd., and others.
Candidiasis Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample